A randomized, double-blind, placebo-controlled clinical study on Yinqi Sanhuang Jiedu Decoction combined with Tongluo Yanggan application in the treatment of hepatitis B-related liver fibrosis
- Conditions
- Hepatitis B-related liver fibrosis
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Meet the diagnostic criteria for chronic hepatitis B;
(2) Meet the diagnostic criteria for liver fibrosis;
(3) Comply with the syndrome differentiation standard of Ganyu and Pixu;
(4) The age is between 18-70 years old, and the gender is not limited;
(5) Willing to participate in this research and sign the informed consent.
(1) Patients with fibrosis caused by other causes of chronic liver disease;
(2) Acute and chronic hepatitis with non-HBV hepadnavirus infection, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hereditary Metabolic liver disease, drug or toxic hepatitis, alcoholic liver disease patients;
(3) pregnant or lactating women and women who plan to be pregnant during the study period;
(4) those who are allergic to the test drug;
(5) can not cooperate with mental disorders Patients in this study, or patients with unstable epilepsy;
(6) Patients with systemic diseases such as severe heart, brain, lung, kidney, and hematopoiesis;
(7) Alcoholism or other unsuitable drug test observers, or In combination with treatment, it is difficult to make a definitive evaluation of the effectiveness and safety of the drug;
(8) Other circumstances that the investigator believes are not suitable for enrollment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptoms of traditional Chinese medicine;LSM;Serum Indices Of Hepatic Fibrosis;The thickness of spleen;liver function;HBV-DNA;
- Secondary Outcome Measures
Name Time Method